Business Context and Reporting Period
Company: MICROVISION, INC.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2001
Business Overview: Microvision develops retinal scanning display technology and optical materials. The company operates through two segments: Microvision (retinal scanning displays) and Lumera Corporation (optical systems components). As of March 31, 2001, the company had an accumulated deficit of $76.4 million and relies on development contracts and equity financing.
Key Financial Metrics
| Metric (in thousands) | Q1 2001 | Q1 2000 |
|---|---|---|
| Revenue | $2,337 | $2,110 |
| Gross Margin | $775 (33.2%) | $642 (30.4%) |
| Net Loss | $(10,220) | $(5,073) |
| Loss Per Share (Basic/Diluted) | $(0.86) | $(0.48) |
| Cash and Cash Equivalents | $22,290 | $3,730 |
| Total Liquid Assets (Cash + Investments) | $54,074 | $N/A |
| Net Cash Used in Operating Activities | $(9,008) | $(4,327) |
| Net Cash Provided by Financing Activities | $21,373 | $2,304 |
| Total Debt (Current + Long-term) | $428 | $N/A |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 11% to $2.3 million, driven entirely by performance on development contracts.
- Expense Surge: Operating expenses more than doubled to $12.2 million. Research and Development (R&D) expenses increased 124% to $8.1 million due to staff expansion, laboratory setup, and new technology licenses (HALO and Optical Materials).
- Net Loss Expansion: Net loss widened to $10.2 million from $5.1 million, primarily due to increased R&D and marketing expenses.
- Liquidity Improvement: Cash and cash equivalents increased significantly from $7.3 million to $22.3 million. This was driven by a $21.4 million capital raise by subsidiary Lumera via the issuance of mandatorily redeemable convertible preferred stock.
- Segment Performance: The Microvision segment reported a loss of $7.9 million, while the Lumera segment reported a loss of $2.9 million.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Product Timeline: The company plans to introduce a production version of a retinal scanning display in late 2001 and a handheld bar code scanner in 2002.
- Spending Trajectory: Management anticipates R&D and marketing expenses will continue to grow substantially as the company hires personnel, expands laboratories, and prepares for commercial product introductions.
- Liquidity: Management believes current cash and investment balances ($54.1 million) will satisfy budgeted requirements for at least the next 12 months, though additional capital may be required to accelerate development or respond to competitive pressures.
- Market Acceptance: No assurance that retinal scanning displays or optical materials will achieve commercial acceptance.
- Profitability: The company has a history of operating losses and expects to incur significant losses in the future. It does not expect significant revenue from product sales in 2001.
- Intellectual Property: Reliance on exclusive licenses from the University of Washington; risk of patent challenges or infringement lawsuits.
- Manufacturing: Lack of current capability to manufacture products in commercial quantities; reliance on third-party partners.
- Customer Concentration: Revenues are highly sensitive to defense and aerospace industry developments and government funding.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $9.0 million quarterly operating cash burn against the $54.1 million liquid asset base.
- Revenue Quality: Confirm the status of the $9.6 million backlog and the mix of government vs. commercial contracts.
- License Obligations: Review the terms of the University of Washington license agreements, specifically royalty payments and exclusivity maintenance requirements.
- Product Milestones: Monitor progress on the late 2001 retinal display launch and 2002 bar code scanner introduction.
- Dilution Risk: Assess the impact of outstanding options (3.16 million) and warrants (463,000) on future share value.